These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30372726)

  • 41. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.
    Rahman HT; Yeh S; Bergstrom CS
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):360-2. PubMed ID: 23061416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel plus bevacizumab for metastatic breast cancer.
    Rossi A; Torri V; Gridelli C
    N Engl J Med; 2008 Apr; 358(15):1637; author reply 1637-8. PubMed ID: 18411431
    [No Abstract]   [Full Text] [Related]  

  • 44. [Pneumothorax after treatment with bevacizumab-containing chemotherapy for breast cancer - a case report].
    Makino T; Kudo S; Ogata T
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):233-5. PubMed ID: 24743204
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A Case of Disseminated Bone Marrow Carcinomatosis Arising from Breast Cancer for Which Paclitaxel and Bevacizumab Treatment Was Effective].
    Kamata A; Hagiwara H; Koizumi M; Sarukawa H; Wada Y; Miyamae T; Abe Y; Takahashi K; Kano T; Natori J; Uchiyama K
    Gan To Kagaku Ryoho; 2016 Jan; 43(1):103-6. PubMed ID: 26809535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
    Manso L; Palomo AG; Pérez Carrión R; Cassinello J; Gallegos Sancho I; Chacón López-Muñiz I; Olier C; Fernández-Aramburo A; Llorca C; González X; Llorente R; Torregrosa D; Álvarez I; Gálve E; Bueno C; Garau I; García MJ; González-Santiago S; Ballesteros AI; Blanco E; Galán A; González S; Perelló A; Cortés-Funes H; Grávalos C
    Anticancer Res; 2015 Dec; 35(12):6941-50. PubMed ID: 26637920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer.
    Gholam D; Chebib A; Hauteville D; Bralet MP; Jasmin C
    Anticancer Drugs; 2007 Aug; 18(7):835-7. PubMed ID: 17581308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bevacizumab plus Paclitaxel Therapy Was Effective for Metastatic Breast Cancer with Dysphagia Due to Mediastinal Lymph Node Metastasis-A Case Report].
    Kodera A; Inoue H; Ogura K; Sakaguchi S; Yukawa H; Matsuoka A; Tanaka N; Kinoshita J; Yoshimatsu K; Naritaka Y; Hirano A
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2276-2278. PubMed ID: 30692436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
    Huober J; Fasching PA; Hanusch C; Rezai M; Eidtmann H; Kittel K; Hilfrich J; Schwedler K; Blohmer JU; Tesch H; Gerber B; Höß C; Kümmel S; Mau C; Jackisch C; Khandan F; Costa SD; Krabisch P; Loibl S; Nekljudova V; Untch M; Minckwitz Gv
    Eur J Cancer; 2013 Jul; 49(10):2284-93. PubMed ID: 23541564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bevacizumab in the treatment of metastatic breast cancer.
    Traina TA
    Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
    Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
    Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bevacizumab in the treatment of metastatic breast cancer: three case reports.
    Ferreira A; Vieira C; Rodrigues A; Pereira D; Rodrigues H; Dávila C; Bento S
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S11-9. PubMed ID: 21490480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Drooger JC; van Tinteren H; de Groot SM; Ten Tije AJ; de Graaf H; Portielje JE; Jager A; Honkoop A; Linn SC; Kroep JR; Erdkamp FL; Hamberg P; Imholz AL; van Rossum-Schornagel QC; Heijns JB; van Leeuwen-Stok AE; Sleijfer S
    Cancer; 2016 Oct; 122(19):2961-70. PubMed ID: 27315546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Biweekly Paclitaxel and Bevacizumab].
    Yoshida T; Goto Y; Sakiyama K; Kimura M
    Gan To Kagaku Ryoho; 2016 Nov; 43(11):1397-1400. PubMed ID: 27899783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
    Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
    Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
    Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical Efficacy of Paclitaxel plus Bevacizumab Combination Therapy for Bone Marrow Carcinomatosis Arising from Breast Cancer - A Case Report].
    Nakayama I
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1391-1392. PubMed ID: 29394644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Usefulness of bevacizumab with paclitaxel for advanced breast cancer - a case report].
    Morishita A; Mitsuhashi S; Fujisawa F; Hirano M; Kojima H
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):761-4. PubMed ID: 23863653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Patient with Recurrent Breast Cancer Who Developed Radiation Esophagitis with Severe Esophageal Stenosis after Combined Bevacizumab and Paclitaxel Therapy-A Case Report].
    Matsuura K; Osaki A; Ichinose Y; Fujimoto A; Nukui A; Saeki T
    Gan To Kagaku Ryoho; 2020 Nov; 47(11):1605-1608. PubMed ID: 33268737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.